Skip to main
GHRS
GHRS logo

GHRS Stock Forecast & Price Target

GHRS Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GH Research PLC has exhibited a strong efficacy profile for its lead candidate, GH001, showing significant improvements in the MADRS scale at Day 2 and Day 8, indicating robust therapeutic potential for treatment-resistant depression. Additionally, the company reports a rapid remission rate of 57.5% within just two hours, which increases to 70% by Day 2, highlighting the quick onset of effect associated with its proprietary therapies. With an estimated enterprise value of $500 million, there is potential for upside as the clinical landscape for psychedelic therapies, particularly in TRD, continues to evolve positively, further bolstering GH Research's long-term outlook.

Bears say

GH Research PLC faces significant challenges that contribute to a negative outlook on its stock. The company's therapies in development have shown inferior efficacy compared to a competitor, with low remission and response rates of only 2.4% to 4.9%, highlighting potential difficulties in achieving clinical success. Furthermore, GH Research is expected to incur net losses until product approval and during the early launch phase, compounded by commercial risks related to slower adoption rates and competitive pressures, which could impact pricing strategies.

GHRS has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GH Research PLC (GHRS) Forecast

Analysts have given GHRS a Strong Buy based on their latest research and market trends.

According to 7 analysts, GHRS has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GH Research PLC (GHRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.